Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adapalene/minocycline - Journey Medical Corporation

Next Previous
Drug Profile

Adapalene/minocycline - Journey Medical Corporation

Alternative Names: FCD 105; Minocycline/adapalene - Foamix pharmaceuticals; Minocycline/adapalene - Journey Medical Corporation

Latest Information Update: 12 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foamix
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Keratolytics; Naphthalenes; Neuroprotectants; Retinoids; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin 6 modulators; Protein 30S ribosomal subunit inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acne vulgaris

Most Recent Events

  • 12 Dec 2022 No development reported - Phase-II for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in USA (Topical)
  • 13 Jan 2022 Journey Medical Corporation purchases Adapalene/minocycline from VYNE Therapeutics
  • 12 Aug 2021 Adapalene/minocycline is available for licensing as of 12 Aug 2021. www.vynetherapeutics.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top